1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier
Product Name
Fiorinal with Codeine C-III

Other means of identification
Product Code
FG00130
Synonyms
butalbital, aspirin, caffeine, and codeine phosphate,

Recommended use of the chemical and restrictions on use
Recommended Use
management of the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate.

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

Details of the supplier of the safety data sheet
Manufacturer
Allergan plc
5 Giralda Farms
Madison, NJ USA 07940
+1-800-272-5525
E-mail address
SDS@Allergan.com

Emergency telephone number
Emergency Telephone
Call CHEMTREC Day or Night
Within USA or Canada: 1-800-424-9300
Outside USA and Canada: +1-703-741-5970 (collect calls accepted)

2. HAZARDS IDENTIFICATION

Classification
OSHA Regulatory Status
This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

Acute toxicity - Oral
Category 3
Serious eye damage/eye irritation
Category 1
Carcinogenicity
Category 2
Reproductive toxicity
Category 2
Specific target organ toxicity (single exposure)
Category 3 - (H335)

Label elements

Emergency Overview

Danger

Hazard statements
H301 - Toxic if swallowed
H318 - Causes serious eye damage
H351 - Suspected of causing cancer
H361 - Suspected of damaging fertility or the unborn child
H335 - May cause respiratory irritation
**H336 - May cause drowsiness or dizziness**

<table>
<thead>
<tr>
<th>Appearance</th>
<th>Capsule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>Solid</td>
</tr>
<tr>
<td>Odor</td>
<td>No information available</td>
</tr>
</tbody>
</table>

**Chemical Name**

**BUTALBITAL USP**

**Chemical Name**

**ASPIRIN USP (80 MESH)**

**Chemical Name**

**CAFFEINE USP(ANHYDROUS & PREMILLED)**

**Donepezil HCL**

**Chemical Name**

**BUTALBITAL USP**

**Chemical Name**

**ASPIRIN USP (80 MESH)**

**Chemical Name**

**CAFFEINE USP(ANHYDROUS & PREMILLED)**

**Donepezil HCL**

**Memantine Hydrochloride**

**Chemical Name**

**BUTALBITAL USP**

**Chemical Name**

**ASPIRIN USP (80 MESH)**

**Chemical Name**

**CAFFEINE USP(ANHYDROUS & PREMILLED)**

**Donepezil HCL**

**Memantine Hydrochloride**

**Medical Conditions Aggravated by Exposure**

**BUTALBITAL USP**

**ASPIRIN USP (80 MESH)**

**CAFFEINE USP(ANHYDROUS & PREMILLED)**

**Donepezil HCL**

**Memantine Hydrochloride**

**Appearance** Capsule  
**Physical state** Solid  
**Odor** No information available

**Symptoms**

The most frequently reported adverse reactions are drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, and intoxicated feeling. The following adverse events are classified as infrequent: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, sluggishness, seizure. Mental confusion, excitement, or depression can also occur due to intolerance, particularly in elderly or debilitated patients, or due to overdosage of this medication.

**Employees administering the product should not experience adverse effects if handled properly.** Adverse effects from therapeutic doses have included the following: Headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, and sluggishness, abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo; Dry mouth, hyperhidrosis, epistaxis, flushing, miosis, salivation; Vomiting, difficulty swallowing, heartburn, anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer, chest pain, hypotensive reaction, palpitations, syncope; Tachycardia; Leg pain and muscle fatigue; Diuresis; Pruritus, allergy, dermatitis, hives, rash, toxic epidermal necrolysis; Kidney impairment, urinary difficulty.

**Cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia.** Adverse effects may include nervousness, tremors, nausea, vomiting, diarrhea, increased urination and trouble sleeping. Possible allergic reaction to material if inhaled, ingested or in contact with skin.

**The most common symptoms seen in therapeutic use include: nausea, diarrhea, insomnia, vomiting, muscle cramp, fatigue and anorexia.**

**When administered for therapeutic use, pre-existing asthma, ulcers, cardiac abnormalities, hepatic, bladder and neurological conditions may be aggravated by exposure.**

**Contraindication include hypersensitivity to any component of this product hepatic impairment.**
Precautionary statements
P264 - Wash face, hands and any exposed skin thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P301 + P310 - IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P321 - Specific treatment (see supplemental first aid instructions on this label)
P330 - Rinse mouth
P280 - Wear eye protection/face protection
P305 + P310 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing
P310 - Immediately call a POISON CENTER or doctor/physician
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical advice/attention

Other Information
Unknown Acute Toxicity
42.05% of the mixture consists of ingredient(s) of unknown toxicity

Over the counter drugs in their solid form are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 20 CFR 1910.1200. However, in an industrial setting where a component’s occupational exposure limit may be surpassed, than can be considered hazardous.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>CAS No.</th>
<th>EINECS</th>
<th>Weight-%</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUTALBITAL USP</td>
<td>77-26-9</td>
<td>201-017-8</td>
<td>15 - 40*</td>
</tr>
<tr>
<td>ASPIRIN USP (80 MESH)</td>
<td>50-78-2</td>
<td>200-064-1</td>
<td>10 - 30*</td>
</tr>
<tr>
<td>CAFFEINE USP (ANHYDROUS &amp; PREMILLED)</td>
<td>58-08-2</td>
<td>200-362-1</td>
<td>10 - 30*</td>
</tr>
<tr>
<td>TALC USP (1656)</td>
<td>14807-96-6</td>
<td>238-877-9</td>
<td>7 - 13*</td>
</tr>
<tr>
<td>MICROCRYSTALLINE CELLULO (AVICEL PH102)</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>7 - 13*</td>
</tr>
<tr>
<td>CORN STARCH NF</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>1 - 5*</td>
</tr>
<tr>
<td>Donepezil HCL</td>
<td>120011-70-3</td>
<td>N/A</td>
<td>0.1 - 1*</td>
</tr>
<tr>
<td>Memantine Hydrochloride</td>
<td>41100-52-1</td>
<td>255-219-6</td>
<td>0.1 - 1*</td>
</tr>
<tr>
<td>Oleic Acid</td>
<td>112-80-1</td>
<td>204-007-1</td>
<td>&lt;0.1*</td>
</tr>
</tbody>
</table>

*The exact percentage (concentration) of composition has been withheld as a trade secret.

### 4. FIRST AID MEASURES

**General advice**
Immediate medical attention is required.

**Eye contact**
Immediately flush with plenty of water. After initial flushing, remove any contact lenses and continue flushing for at least 15 minutes. Keep eye wide open while rinsing. Call a physician immediately.

**Skin Contact**
Immediate medical attention is required. Wash off immediately with soap and plenty of water while removing all contaminated clothes and shoes.

**Inhalation**
Immediate medical attention is required. Remove to fresh air. If not breathing, give artificial respiration. Avoid direct contact with skin. Use barrier to give mouth-to-mouth resuscitation.
Ingestion
Do NOT induce vomiting. Call a physician or poison control center immediately. Never give anything by mouth to an unconscious person. Drink plenty of water.

Chemical Name
BUTALBITAL USP

Note to physicians
This product should only be given to patients by persons experienced in management of patients receiving the type of therapy intended for this product. Treatment consists primarily of management of barbiturate intoxication, reversal of the effects of codeine, and the correction of the acid-base imbalance due to salicylism. Vomiting should be induced mechanically or with emetics in the conscious patient. Gastric lavage may be used if the pharyngeal and laryngeal reflexes are present and if less than 4 hours have elapsed since ingestion. A cuffed endotracheal tube should be inserted before gastric lavage of the unconscious patient and when necessary to provide assisted respiration.

Diuresis, alkalization of the urine, and correction of electrolyte disturbances should be accomplished through administration of intravenous fluids such as 1% sodium bicarbonate and 5% dextrose in water. Meticulous attention should be given to maintaining adequate pulmonary ventilation. The value of vasoressor agents such as Norepinephrine or Phenylephrine Hydrochloride in treating hypotension is questionable since they increase vasoconstriction and decrease blood flow. However, if prolonged support of blood pressure is required, Norepinephrine Bitartrate (Levophed) may be given I.V. with the usual precautions and serial blood pressure monitoring. In severe cases of intoxication, peritoneal dialysis, hemodialysis, or exchange transfusion may be lifesaving. Hypoprothrombinemia should be treated with vitamin K, intravenously. Methemoglobinemia over 30% should be treated with methylene blue by slow intravenous administration. Naloxone, a narcotic antagonist, can reverse respiratory depression and coma associated with opioid overdose. Typically, a dose of 0.4 mg to 2 mg is given parenterally and may be repeated if an adequate response is not achieved. Since the duration of action of codeine may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression. May be habit forming.

ASPIRIN USP (80 MESH)
Aspirin USP is contraindicated under the following conditions: Hypersensitivity or intolerance; patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von Willebrand’s disease, the thrombocytopenias, thrombasthenia, and other ill-defined hereditary platelet dysfunctions, severe vitamin K deficiency and severe liver damage); patients with the syndrome of nasal polyps, angioedema, and bronchospastic reactivity to aspirin or other nonsteroidal anti-inflammatory drugs. Anaphylactoid reactions have occurred in such patients; peptic ulcer or other serious gastrointestinal lesions; patients with porphyria.

CAFFEINE USP (ANHYDROUS & PREMILLED)
Treatment of caffeine overdose is primarily symptomatic and supportive. Caffeine levels have been shown to decrease after exchange transfusions. Convulsions may be treated with intravenous administration of diazepam or a barbiturate such as pentobarbital sodium.

Donepezil HCL
Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Tertiary anticholinergics such as
atropine may be used as an antidote for ARICEPT overdosage. Intravenous atropine sulfate titrated to effect is recommended: an initial dose of 1.0 to 2.0 mg IV with subsequent doses based upon clinical response.

Memantine Hydrochloride

Conditions that raise urine pH may decrease urinary elimination of Memantine, resulting in increased plasma levels of memantine.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media
None known.

Specific hazards arising from the chemical
Fire may produce irritating, corrosive and/or toxic gases.

Explosion data
Sensitivity to Mechanical Impact
Not impact sensitive.

Sensitivity to Static Discharge
Fine dust dispersed in air, in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.

Protective equipment and precautions for firefighters
As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions
Use personal protective equipment as required. Keep people away from and upwind of spill/leak.

Environmental precautions
Prevent further leakage or spillage if safe to do so. Prevent product from entering drains. See Section 12 for additional ecological information.

Methods for containment
Prevent further leakage or spillage if safe to do so. Cover powder spill with plastic sheet or tarp to minimize spreading. Dike far ahead of liquid spill for later disposal.

Methods for cleaning up
Use personal protective equipment as required. Cover powder spill with plastic sheet or tarp to minimize spreading and keep powder dry. Take up mechanically, placing in appropriate containers for disposal. Avoid creating dust. Clean contaminated surface thoroughly.

7. HANDLING AND STORAGE

Advice on safe handling
Avoid contact with skin, eyes or clothing. Use personal protective equipment as required. Wash contaminated clothing before reuse. Do not breathe dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product.

Storage Conditions
Keep container tightly closed in a dry and well-ventilated place. Keep out of the reach of children.

Incompatible materials
None known based on information supplied.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure Guidelines

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>ACGIH TLV</th>
<th>OSHA PEL</th>
<th>NIOSH IDLH</th>
<th>Allergan OEL (ug/m³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUTALBITAL USP</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>100 ug/m³</td>
</tr>
<tr>
<td>77-26-9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASPIRIN USP (80 MESH)</td>
<td>TWA: 5 mg/m³</td>
<td>(vacated) TWA: 5 mg/m³</td>
<td>TWA: 5 mg/m³</td>
<td>1778 ug/m³</td>
</tr>
<tr>
<td>CAS Number</td>
<td>Description</td>
<td>TWA Limit</td>
<td>TWA Limit</td>
<td>STEL Limit</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>-----------</td>
<td>-----------</td>
<td>------------</td>
</tr>
<tr>
<td>50-14-6</td>
<td>CAFFEINE USP(ANHYDROUS &amp; PREMILLED) 58-08-2</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>14807-96-6</td>
<td>TALC USP(1656)</td>
<td>2 mg/m³ particulate matter containing no asbestos and &lt;1% crystalline silica, respirable particulate matter</td>
<td>(vacated) TWA: 2 mg/m³ respirable dust &lt;1% Crystalline silica, containing &lt;1% Asbestos TWA: 20 mppcf if 1% Quartz or more; use Quartz limit</td>
<td>IDLH: 1000 mg/m³ TWA: 2 mg/m³ containing no Asbestos and &lt;1% Quartz respirable dust</td>
</tr>
<tr>
<td>9004-34-6</td>
<td>MICROCRYSTALLINE CELLULO(avicel PH102)</td>
<td>10 mg/m³ total dust</td>
<td>TWA: 15 mg/m³ total dust TWA: 5 mg/m³ respirable fraction (vacated) TWA: 15 mg/m³ total dust (vacated) TWA: 5 mg/m³ respirable fraction (vacated) TWA: 5 mg/m³ (vacated) STEL: 10 mg/m³</td>
<td>TWA: 10 mg/m³ total dust TWA: 5 mg/m³ respirable dust (vacated) TWA: 1 mg/m³</td>
</tr>
<tr>
<td>9005-25-8</td>
<td>CORN STARCH NF 9005-25-8</td>
<td>10 mg/m³</td>
<td>TWA: 15 mg/m³ total dust TWA: 5 mg/m³ respirable fraction (vacated) TWA: 15 mg/m³ total dust (vacated) TWA: 5 mg/m³ respirable fraction</td>
<td>TWA: 10 mg/m³ total dust TWA: 5 mg/m³ respirable dust</td>
</tr>
<tr>
<td>120011-70-3</td>
<td>Donepezil HCL</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>41100-52-1</td>
<td>Memantine Hydrochloride 41100-52-1</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**NIOSH IDLH** Immediately Dangerous to Life or Health

**Other Information**
Vacated limits revoked by the Court of Appeals decision in AFL-CIO v. OSHA, 965 F.2d 962 (11th Cir., 1992).

**Appropriate engineering controls**

**Engineering Controls**
The health hazard risks of handling this material are dependent on factors, such as physical form and quantity. Site specific risk assessments should be conducted to determine the appropriate exposure control measures. Good general ventilation should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

**Individual protection measures, such as personal protective equipment**

**Eye/face protection**
No eye protection is normally needed during medical administration of this product. During operations in which dusts of the product may be generated, safety glasses should be considered.

**Skin and body protection**
During medical administration of this product, medical latex or nitrile gloves should be worn to avoid absorption of the product. Use appropriate protective clothing for the task (e.g., lab coat, etc.).

**Respiratory protection**
Respiratory protection is generally not needed during routine conditions of use of this product. If respiratory protection is needed, use only respiratory protection authorized under appropriate regional regulations.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

**Information on basic physical and chemical properties**
10. STABILITY AND REACTIVITY

Reactivity
Not defined as reactive substance

Chemical stability
Stable under normal conditions.

Possibility of Hazardous Reactions
None under normal processing.

Conditions to avoid
Aerosol formation.

Incompatible materials
None known based on information supplied.

Hazardous Decomposition Products
None known based on information supplied.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Acute toxicity

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Inhalation</th>
<th>Eye contact</th>
<th>Skin Contact</th>
<th>Ingestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUTALBITAL USP</td>
<td>Inhalation of airborne dusts</td>
<td>May cause irritation. Flush</td>
<td>May cause irritation. Avoid</td>
<td>May cause irritation, slightly</td>
</tr>
<tr>
<td></td>
<td>generated by this product</td>
<td>with copious quantities of</td>
<td>contact. Flush with copious</td>
<td>bitter taste, and toxicity.</td>
</tr>
</tbody>
</table>
may slightly irritate the nose, throat, and lungs. Symptoms are generally alleviated upon breathing fresh air.

**ASPIRIN USP (80 MESH)**
Inhalation of airborne dusts generated by this product may slightly irritate the nose, throat, and lungs. Symptoms are generally alleviated upon breathing fresh air.

Contact with the eyes of airborne dusts generated by this product may cause mild to moderate irritation, redness, and tearing.

This material is readily absorbed through the skin and excessive amounts can cause systemic toxicity. Causes skin irritation.

Ingestion is not a significant route of occupational overexposure. Acute ingestion of large quantities of this product caused by poor hygiene practices may cause adverse symptoms. Symptoms of ingestion overexposure may include light-headedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, and intoxicated feeling. Symptoms of prolonged or repeated ingestion, as may occur when poor industrial hygiene is practiced.

**CAFFEINE USP (ANHYDROUS & PREMILLED)**
Inhalation of this compound may irritate the nose, throat, and lungs. No information is available on other possible effects.

Contact with the eyes of airborne dusts generated by this product may cause mild to moderate irritation, redness, and tearing.

Contact with the skin may cause irritation. Prolonged or repeated skin contact may cause dermatitis (dry, red skin).

Ingestion is not a significant route of occupational overexposure. If swallowed, irritation of the gastrointestinal tract may occur with nausea, vomiting, and diarrhea.

### Chemical Name

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Oral LD50</th>
<th>Dermal LD50</th>
<th>Inhalation LC50</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASPIRIN USP (80 MESH)</strong></td>
<td>= 200 mg/kg (Rat)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>CAFFEINE USP (ANHYDROUS &amp; PREMILLED)</strong></td>
<td>= 192 mg/kg (Rat)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>MICROCRYSTALLINE CELLULO (AVICEL PH102)</strong></td>
<td>&gt; 5 g/kg (Rat)</td>
<td>&gt; 2 g/kg (Rabbit)</td>
<td>&gt; 5800 mg/m³ (Rat) 4 h</td>
</tr>
<tr>
<td><strong>Donepezil HCL</strong></td>
<td>32.6 mg/kg (rat)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Memantine Hydrochloride</strong></td>
<td>325 mg/kg Oral Rat (Female)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Oleic Acid</strong></td>
<td>= 25 g/kg (Rat)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Germ cell mutagenicity</th>
<th>Carcinogenicity</th>
<th>Reproductive toxicity</th>
<th>Effects on or via lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BUTALBITAL USP</strong></td>
<td>No adequate studies have been conducted in animals to determine whether this medication has the potential for carcinogenesis, mutagenesis, or impairment of fertility.</td>
<td>No information available.</td>
<td>No congenital abnormalities were uncovered in 112 pregnancies that included first trimester exposure to butalbital. One case report has described severe neonatal withdrawal that began within 2 days of birth in a male infant whose mother took 150 mg butalbital daily during the last 2 months of pregnancy. The barbiturate had been prescribed in a fixed-combination headache medication. The neonatal symptoms of barbiturate withdrawal were characterized as including over-activity, irritability, vasomotor instability and</td>
<td>This medication is excreted in breast milk in small amounts, but the significance of their effects on nursing infants is unknown. Because of the potential for serious adverse reaction in nursing infants from this medication, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Information Available</td>
<td>Suspected Carcinogen</td>
<td>Known Mutageneicity</td>
<td>Carcinogenicity in Humans</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>------------------------------------------------------------</td>
<td>----------------------</td>
<td>---------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>ASPIRIN USP (80 MESH)</td>
<td>No information available.</td>
<td>Not suspected</td>
<td>None known.</td>
<td>It is not known whether this drug is excreted in human milk. Because most drugs are excreted in human milk, if use of this drug is deemed essential, the patient should stop nursing.</td>
</tr>
<tr>
<td>CAFFEINE USP (ANHYDROUS &amp; PREMILLED)</td>
<td>Caffeine (as caffeine base) increased the sister chromatid exchange (SCE) SCE/cell metaphase (exposure time dependent) in an in vivo mouse metaphase analysis. Caffeine also potentiated the genotoxicity of known mutagens and enhanced the micronuclei formation (5-fold) in folate-deficient mice. However, caffeine did not increase chromosomal aberrations in an in vitro Chinese hamster ovary cell (CHO) and human lymphocyte assays and was not mutagenic in an in vitro CHO/hypoxanthine guanine phosphoribosyltransferase (HGPRT) gene mutation assay, except at cytotoxic concentrations. In addition, caffeine was not clastogenic in an in vivo mouse micronucleus assay.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In a 2-year study in Sprague-Dawley rats, caffeine (as caffeine base) administered in drinking water was not carcinogenic in the offspring at doses up to 102 mg/kg or in female rats at doses up to 170 mg/kg (approximately 2 and 4 times, respectively, the maximum recommended intravenous loading dose for infants on a mg/m² basis). In an 18-month study in C57BL/6 mice, no evidence of tumorigenicity was seen at dietary doses up to 55 mg/kg (less than the maximum recommended intravenous loading dose for infants on a mg/m² basis).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>This study evaluated the timing and amount of caffeine intake by women and men undergoing in vivo fertilization/IVF and gamete intra-Fallopian transfer (GIFT) on oocyte retrieval, sperm parameters, fertilization, multiple gestations, miscarriage, and live births. A prospective study of 221 couples was conducted in Southern California between 1993 and 1998. 'Usual' caffeine intake during lifetime and 1 year prior to attempt, caffeine intake during the week of the initial clinic visit, as well as intake during the week of the procedure, was evaluated from beverages (coffee, soda, tea) and chocolates. Not achieving a live birth was significantly associated with 'usual' female caffeine consumption (adjusted odds ratios (95% confidence intervals): 3.1 (1.1, 9.7) and 3.9 (1.3, 11.6) for intake of &gt;2-50 and 50 mg/day, compared with 0-2 mg/day) and consumption during the week of the initial visit [2.9 (1.1, 7.5) and 3.8 (1.4, 10.7)] female compared with 0-2 mg/day, although caffeine use was low. Infant gestational age decreased by 3.8 (-6.9, -0.7) or 3.5 (-6.7, -0.3) weeks for women who consumed &gt;50 mg/day of caffeine ‘usually’ or during the week of the initial visit. The odds of having multiple gestations increased by 2.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Detectable amounts of this compound have been identified in the milk of women receiving this drug. Caution should be exercised when taking this compound is administered to nursing women.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Caffeine intake was not significantly associated with other outcomes. This is the first IVF/GIFT study to report any effect of caffeine on live births, gestational age, and multiple gestations. If these findings are replicated, caffeine use should be minimized prior to and while undergoing IVF/GIFT. Concern for the teratogenicity of caffeine is not relevant when administered to infants. In studies performed in adult animals, caffeine (as caffeine base) administered to pregnant mice as sustained release pellets at 50 mg/kg (less than the maximum recommended intravenous loading dose for infants on a mg/m² basis), during the period of organogenesis, caused a low incidence of cleft palate and exencephaly in the fetuses. There are no adequate and well-controlled studies in pregnant women.

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>STOT - single exposure</th>
<th>STOT - repeated exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donepezil HCL</td>
<td>Not mutagenic in the standard battery of tests.</td>
<td>This product does not contain any known or suspected reproductive hazards.</td>
</tr>
<tr>
<td>Memantine Hydrochloride</td>
<td>Animal studies in mice and rats have not shown carcinogenicity.</td>
<td>Studies in rats have not shown fertility impairment. Decreased pup weights and an increase in incompletely ossified vertebrae was observed at slightly maternally toxic doses with the NOEL of approximately 3 times the maximum recommended human therapeutic dose.</td>
</tr>
<tr>
<td>Oleic Acid</td>
<td>Not Suspected of being a Mutagen.</td>
<td>Not suspected of being a human carcinogen.</td>
</tr>
</tbody>
</table>

**Chemical Name**

**STOT - single exposure**

**STOT - repeated exposure**

**BUTALBITAL USP**

Butalbital may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Alcohol and other CNS depressants may produce an additive CNS depression. Butalbital may be habit-forming and is a Schedule III controlled substance. No information available.

**Chronic toxicity**

May cause adverse effects on the bone marrow and blood-forming system. May cause adverse liver effects.

**Target Organ Effects**

Blood, Central nervous system, Central Vascular System (CVS), Eyes, Gastrointestinal tract (GI), kidney, liver, Respiratory system, Skin, Urinary Tract, Musculo-skeletal system.

**Numerical measures of toxicity - Product Information**
Unknown Acute Toxicity

42.05% of the mixture consists of ingredient(s) of unknown toxicity

The following values are calculated based on chapter 3.1 of the GHS document.

- **ATEmix (oral)**: 232 mg/kg
- **ATEmix (dermal)**: 11602 mg/kg
- **ATEmix (inhalation-dust/mist)**: 33.6 mg/L

12. ECOLOGICAL INFORMATION

Ecotoxicity

54.45% of the mixture consists of components(s) of unknown hazards to the aquatic environment

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Algae/aquatic plants</th>
<th>Fish</th>
<th>Crustacea</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPIRIN USP (80 MESH) 50-78-2</td>
<td>N/A</td>
<td>N/A</td>
<td>100: 48 h Daphnia magna mg/L EC50</td>
</tr>
<tr>
<td>CAFFEINE USP(ANHYDROUS &amp; PREMILLED) 58-08-2</td>
<td>N/A</td>
<td>151: 96 h Pimephales promelas mg/L LC50 flow-through</td>
<td>182.12: 4 h Daphnia species mg/L EC50</td>
</tr>
<tr>
<td>TALC USP(1656) 14807-96-6</td>
<td>N/A</td>
<td>100: 96 h Brachydianio rerio g/L LC50 semi-static</td>
<td>N/A</td>
</tr>
<tr>
<td>Oleic Acid 112-80-1</td>
<td>N/A</td>
<td>205: 96 h Pimephales promelas mg/L LC50 static</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Persistence and degradability</th>
<th>Bioaccumulation</th>
<th>Mobility</th>
<th>Partition coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUTALBITAL USP 77-26-9</td>
<td>None known</td>
<td>Based on the BCF, the potential for bioaccumulation in aquatic organisms is low.</td>
<td>Mobility in soil High</td>
<td>1.87 (est)</td>
</tr>
<tr>
<td>ASPIRIN USP (80 MESH) 50-78-2</td>
<td>No information available</td>
<td>No information available</td>
<td>High Mobility in soil</td>
<td>1.19</td>
</tr>
<tr>
<td>CAFFEINE USP(ANHYDROUS &amp; PREMILLED) 58-08-2</td>
<td>No information available</td>
<td>Low</td>
<td>Low mobility in soil</td>
<td>log Kow = -0.07</td>
</tr>
<tr>
<td>Donepezil HCL 120011-70-3</td>
<td>This compound has not been tested for persistence or biodegradability</td>
<td>Based on the BCF, the potential for bioaccumulation in aquatic organisms is high.</td>
<td>This product has not been tested for mobility in soil</td>
<td>Log P = 4.708 (predict.)</td>
</tr>
<tr>
<td>Memantine Hydrochloride 41100-52-1</td>
<td>N/A</td>
<td>Based on the BCF, the potential for bioaccumulation in aquatic organisms is high.</td>
<td>Low mobility in soil</td>
<td>3.28</td>
</tr>
</tbody>
</table>

Other adverse effects

No information available

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Disposal of wastes

Disposal should be in accordance with applicable regional, national and local laws and regulations.

Contaminated packaging

Do not reuse container. Dispose of contents/containers in accordance with local regulations.

14. TRANSPORT INFORMATION

| DOT                                      | Not regulated         |
| TDG                                      | Not regulated         |
| ICAO (air)                               | Not regulated         |
IATA  Not regulated
IMDG  Not regulated
ADR  Not regulated
ADN  Not regulated

15. REGULATORY INFORMATION

International Inventories
TSCA  Not Listed
DSL/NDSL  Not Listed
EINECS/ELINCS  Not Listed

Legend:
TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

US Federal Regulations

Carcinogenicity
This product contains one or more substances which are classified by IARC as carcinogenic to humans (Group I), probably carcinogenic to humans (Group 2A) or possibly carcinogenic to humans (Group 2B)

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>ACGIH</th>
<th>IARC</th>
<th>NTP</th>
<th>OSHA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAFFEINE USP(ANHYDROUS &amp; PREMILLED)</td>
<td></td>
<td>Group 3</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>TALC USP(1656)</td>
<td></td>
<td>Group 3</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>MICROCRYSTALLINE CELLULO(AVICEL PH102)</td>
<td></td>
<td>Group 1</td>
<td>Known</td>
<td>X</td>
</tr>
</tbody>
</table>

IARC (International Agency for Research on Cancer)
Group 1 - Carcinogenic to Humans
Not classifiable as a human carcinogen
NTP (National Toxicology Program)
Known - Known Carcinogen
OSHA (Occupational Safety and Health Administration of the US Department of Labor)
X - Present

SARA 313
Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372

SARA 311/312 Hazard Categories
- Acute health hazard: Yes
- Chronic Health Hazard: No
- Fire hazard: No
- Sudden release of pressure hazard: No
- Reactive Hazard: No

CWA (Clean Water Act)
This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42)

CERCLA
This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material
US State Regulations

California Proposition 65
This product contains the following Proposition 65 chemicals

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>California Proposition 65</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUTALBITAL USP - 77-26-9</td>
<td>Developmental</td>
</tr>
<tr>
<td>ASPIRIN USP (80 MESH) - 50-78-2</td>
<td>Developmental</td>
</tr>
<tr>
<td></td>
<td>Female Reproductive</td>
</tr>
<tr>
<td>CODEINE PHOSPHATE PDR USP - 52-28-8</td>
<td>Developmental</td>
</tr>
<tr>
<td>MICROCRYSTALLINE CELLULO(AVICEL PH102) - 9004-34-6</td>
<td>Carcinogen</td>
</tr>
</tbody>
</table>

U.S. State Right-to-Know Regulations

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>New Jersey</th>
<th>Massachusetts</th>
<th>Pennsylvania</th>
</tr>
</thead>
<tbody>
<tr>
<td>TALC USP(1656) 14807-96-6</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MICROCRYSTALLINE CELLULO(AVICEL PH102) 9004-34-6</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Oleic Acid 112-80-1</td>
<td>-</td>
<td>-</td>
<td>X</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Revision Date: 16-Jul-2019
Revision Note: No information available
Disclaimer: The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

End of Safety Data Sheet